NASDAQ · JBIO
Jade Biosciences, Inc.
$13.92-$0.32 (-2.22%)
Jade Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.27% below the high.
Loading market information…
NASDAQ · NVCN · USD
Stock price, earnings
Quote as of Apr 10, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Neovasc Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Neovasc Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Neovasc Inc. is a specialized medical technology enterprise focused on the development, production, and worldwide distribution of products for the cardiac health sector, with a significant presence across Europe and other international markets. The company's key innovations feature the Tiara system, an advanced transcatheter technology for managing mitral valve disease, and the Neovasc Reducer, which offers a therapeutic option for patients suffering from refractory angina. Founded in 2000, the organization initially operated as Medical Ventures Corp. before adopting the name Neovasc Inc. in July 2008. Its corporate headquarters are situated in Richmond, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:09 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $703.42K-39.36% vs estimate |
| Q2 2021 | Aug 10, 2021 | -$3.25-44.44% vs estimate | $633.07K-45.43% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.92-$0.32 (-2.22%)
Jade Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.27% below the high.
$2.95-$0.23 (-7.23%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.33% below the high.
$0.10-$0.00 (-0.21%)
Zomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.15% below the high.
$0.35+$0.00 (+0.64%)
Asensus Surgical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.87% below the high.
$1.20-$0.08 (-5.88%)
Berkeley Lights, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.78% below the high.
$1.27$0.00 (0.0%)
IGM Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.36% below the high.
$1.30+$0.03 (+2.36%)
Zynerba Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.14% below the high.
$6.01+$0.10 (+1.69%)
Lifeward Ltd.’s quoted price sits in the lower half of its reported 52-week range, 37.46% below the high.
